EE05026B1 - Fulvestrandi kasutamine resistentse rinnav„hi ravis - Google Patents

Fulvestrandi kasutamine resistentse rinnav„hi ravis

Info

Publication number
EE05026B1
EE05026B1 EEP200200574A EEP200200574A EE05026B1 EE 05026 B1 EE05026 B1 EE 05026B1 EE P200200574 A EEP200200574 A EE P200200574A EE P200200574 A EEP200200574 A EE P200200574A EE 05026 B1 EE05026 B1 EE 05026B1
Authority
EE
Estonia
Prior art keywords
fulvestrant
treatment
breast cancer
resistant breast
resistant
Prior art date
Application number
EEP200200574A
Other languages
English (en)
Estonian (et)
Inventor
Thurlimann Beat
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05026(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200574A publication Critical patent/EE200200574A/xx
Publication of EE05026B1 publication Critical patent/EE05026B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200200574A 2000-04-05 2001-04-02 Fulvestrandi kasutamine resistentse rinnav„hi ravis EE05026B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (2)

Publication Number Publication Date
EE200200574A EE200200574A (et) 2004-04-15
EE05026B1 true EE05026B1 (et) 2008-06-16

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200574A EE05026B1 (et) 2000-04-05 2001-04-02 Fulvestrandi kasutamine resistentse rinnav„hi ravis

Country Status (28)

Country Link
US (2) US20030158166A1 (cg-RX-API-DMAC7.html)
EP (2) EP1586323A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528919A (cg-RX-API-DMAC7.html)
KR (1) KR100757764B1 (cg-RX-API-DMAC7.html)
CN (1) CN1431905A (cg-RX-API-DMAC7.html)
AT (1) ATE306270T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001244372B2 (cg-RX-API-DMAC7.html)
BR (1) BR0109789A (cg-RX-API-DMAC7.html)
CA (1) CA2403608A1 (cg-RX-API-DMAC7.html)
CH (1) CH1272195H1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303096B6 (cg-RX-API-DMAC7.html)
DE (1) DE60113975T2 (cg-RX-API-DMAC7.html)
DK (1) DK1272195T3 (cg-RX-API-DMAC7.html)
EE (1) EE05026B1 (cg-RX-API-DMAC7.html)
ES (1) ES2248300T3 (cg-RX-API-DMAC7.html)
GB (1) GB0008172D0 (cg-RX-API-DMAC7.html)
HU (1) HU230064B1 (cg-RX-API-DMAC7.html)
IL (2) IL151932A0 (cg-RX-API-DMAC7.html)
IS (1) IS2869B (cg-RX-API-DMAC7.html)
MX (1) MXPA02009744A (cg-RX-API-DMAC7.html)
NO (1) NO329949B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ539603A (cg-RX-API-DMAC7.html)
PL (1) PL201175B1 (cg-RX-API-DMAC7.html)
RU (1) RU2265438C2 (cg-RX-API-DMAC7.html)
SK (1) SK287779B6 (cg-RX-API-DMAC7.html)
UA (1) UA80388C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001074366A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207538B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0210898A (pt) * 2001-07-07 2004-06-22 Astrazeneca Ab Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
US8324194B2 (en) * 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
KR20140048881A (ko) * 2011-05-09 2014-04-24 유니버시티 오브 버지니아 페이턴트 파운데이션 암 치료 조성물 및 방법
BR112013029758A2 (pt) 2011-05-20 2018-10-09 Capital, Business Y Gestion De Finanzas S.L. composição farmacêutica
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI878810B (zh) 2017-09-11 2025-04-01 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
CA3101421C (en) * 2018-05-24 2024-06-18 Kashiv Biosciences, Llc Prodrugs of fulvestrant
CA3145867A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
WO2021174195A2 (en) * 2020-02-29 2021-09-02 The University Of Vermon Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
AU4437201A (en) 2001-10-15
DE60113975D1 (de) 2006-02-23
IS6576A (is) 2002-10-01
PL201175B1 (pl) 2009-03-31
US20030158166A1 (en) 2003-08-21
EP1586323A1 (en) 2005-10-19
EP1272195A1 (en) 2003-01-08
IL151932A0 (en) 2003-04-10
JP2003528919A (ja) 2003-09-30
IS2869B (is) 2014-03-15
RU2265438C2 (ru) 2005-12-10
DK1272195T3 (da) 2006-01-16
CH1272195H1 (cg-RX-API-DMAC7.html) 2019-10-15
BR0109789A (pt) 2003-01-21
ATE306270T1 (de) 2005-10-15
NO20024735L (no) 2002-11-27
CZ20023309A3 (cs) 2003-02-12
MXPA02009744A (es) 2004-02-26
HU230064B1 (hu) 2015-06-29
ES2248300T3 (es) 2006-03-16
CN1431905A (zh) 2003-07-23
NO20024735D0 (no) 2002-10-02
EP1272195B1 (en) 2005-10-12
HUP0300339A2 (hu) 2003-06-28
US20110183949A1 (en) 2011-07-28
DE60113975T2 (de) 2006-06-22
AU2001244372B2 (en) 2006-02-16
ZA200207538B (en) 2003-12-19
CZ303096B6 (cs) 2012-04-04
KR20030007501A (ko) 2003-01-23
HUP0300339A3 (en) 2009-01-28
KR100757764B1 (ko) 2007-09-12
PL357936A1 (en) 2004-08-09
CA2403608A1 (en) 2001-10-11
NZ539603A (en) 2008-02-29
EE200200574A (et) 2004-04-15
GB0008172D0 (en) 2000-05-24
WO2001074366A1 (en) 2001-10-11
SK14292002A3 (sk) 2003-08-05
NO329949B1 (no) 2011-01-31
SK287779B6 (sk) 2011-09-05
IL151932A (en) 2007-07-04
UA80388C2 (en) 2007-09-25
HK1051498A1 (en) 2003-08-08

Similar Documents

Publication Publication Date Title
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
EE05026B1 (et) Fulvestrandi kasutamine resistentse rinnav„hi ravis
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
FR08C0013I2 (fr) Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer
BRPI0407305A (pt) Ligantes do receptor de canabinóides e seus usos
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
ATE307601T1 (de) Brustkrebsbehandlung mittels natürlicher ätherischer öle
MY138883A (en) Use of asiatic acid for treatment of cencer
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
DE60223576D1 (de) Hautbehandlungszusammensetzung
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL161059A0 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
DE60107034D1 (de) Misch- und Ladeöffnung zur medizinischen Behandlung
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
PL366066A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka sutka
TW200503731A (en) Method of treatment
DE60221068D1 (de) Gerät zur tiefenwirksamen Hauttherapie
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
NO20010630D0 (no) Krummet trapp og trappetrinn for krummet trapp
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk
UA28113C2 (uk) Спосіб експрес-тестування ефективності реабілітації здоров'я людини
ATE297745T1 (de) Chemische modifizierung von harn von säugern

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231